Anticytokine Autoantibodies in COVID-19

COVID-19 中的抗细胞因子自身抗体

• 批准号: 10712566
• 负责人: Steven Holland
• 金额: $ 0.43万
• 依托单位: NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10712566
• 关键词: 2019-nCoV; Autoantibodies; Biological Assay; COVID-19; COVID-19 patient; COVID-19 surveillance; Clinical Protocols; Country; Disease Outcome; Employee; Enrollment; Goals; Individual; Infection; Interferon Type I; Italy; Longitudinal cohort study; Manuscripts; Patients; Polymerase Chain Reaction; Protocols documentation; Publishing; Reporting; Reverse Transcription; SARS-CoV-2 exposure; SARS-CoV-2 infection; Sampling; Science; Severity of illness; Swab; Testing; United States National Institutes of Health; antibody test; clinical center; cohort; nasopharyngeal swab; neutralizing antibody; prospective; saliva sample; severe COVID-19

For Autoantibody study, patient samples from the COVID-19 cohort obtained by Dr. Notarangelo, and control samples, were comprehensively screened for the presence of anticytokine autoantibodies. Functional studies were also performed to verify if positive samples contained neutralizing antibodies. We found that approximately 10% of patients with severe COVID-19 had high levels fo neutralizing antibodies against type I interferons. A manuscript describing these results was published in Science. For COVID-19 surveillance, a new clinical protocol was initiated at the NIH Clinical Center (20-I-0117). This is a prospective longitudinal cohort study of individuals with exposure to severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2). The aim is to correlate results of reverse transcription-polymerase chain reaction (RT-PCR) using various sample types, assays, and culture. We will perform serial screenings of NIH employees who have had contact with reported, suspected or known cases. We will also enroll individuals with previous or current infection who are asymptomatic at enrollment. The serial screenings will be done at multiple timepoints over 28 days using RT-PCR tests of nasopharyngeal (NP) swabs, saliva samples, midturbinate swabs, antibody assays and culture. Enrollment on this protocol has recently begun.

对于自身抗体研究，对 Notarangelo 博士获得的 COVID-19 队列患者样本和对照样本进行了全面筛查，以确定是否存在抗细胞因子自身抗体。还进行了功能研究，以验证阳性样本是否含有中和抗体。我们发现，大约 10% 的重症 COVID-19 患者具有高水平的 I 型干扰素中和抗体。描述这些结果的手稿发表在《科学》杂志上。 对于 COVID-19 监测，NIH 临床中心启动了一项新的临床方案 (20-I-0117)。 这是一项针对严重急性呼吸综合征冠状病毒 2 (SARS-CoV-2) 接触者的前瞻性纵向队列研究。目的是使用不同的样本类型、检测方法和培养物来关联逆转录聚合酶链式反应 (RT-PCR) 的结果。我们将对接触过报告病例、疑似病例或已知病例的 NIH 员工进行系列筛查。我们还将招募既往或当前感染且在入组时无症状的个人。一系列筛查将在 28 天内的多个时间点进行，使用鼻咽 (NP) 拭子、唾液样本、中鼻甲拭子的 RT-PCR 检测、抗体测定和培养。该协议的注册最近已开始。